Nutritional status in pulmonary arterial hypertension

Chermaine T. Kwant1 | Frans A. L. van der Horst2 | Harm J. Bogaard1 | Frances S. de Man1 | Anton Vonk Noordegraaf1

1Departments of Pulmonary Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
2Department of clinical chemistry, Reinier Medical Diagnostic Center, Delft, The Netherlands

Correspondence
Chermaine T. Kwant, PhD, Department of Pulmonary Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Email: c.kwant@amsterdamumc.nl; Twitter: @ChermaineKwant

Funding information
Janssen-Cilag B.V.

Abstract
Nutritional deficiencies have been described in patients with pulmonary arterial hypertension (PAH), such as in iron and vitamin D. However, an extensive description of vitamin and mineral status is lacking and until now there is no data on dietary intake in PAH patients. We analyzed blood samples and determined nutritional intake using a food frequency questionnaire (HELIUS) in a cohort of prevalent PAH patients at a single center in Amsterdam, the Netherlands. Quality of life (QoL) was assessed by the SF-36 questionnaire. In total, 37 patients were included (6 males, 31 females; 48 ± 16 years). The dietary intake of sugar was above 25 g in 87% of the patients and fluid intake was above 1500 ml in 78% of the patients. Sodium intake was below 1800 mg in the majority (56%) of the patients. Sugar and fluid intake were linear related. We confirm previously observed deficiencies of iron and vitamin D in our study population. In addition, we observed a functional vitamin B12 deficiency in 29% of patients, which coincided with an increased expression of methylmalonic acid. 60% of patients had a low vitamin K1 status (<0.8 nmol/L). Finally, 40% of patients had selenium levels below <100 μg/L and low selenium levels associated with reduced vitality in these patients.

Besides the known deficiencies in iron and vitamin D levels, we observed in a subset of patients signs of vitamin B12, vitamin K1 and selenium deficiencies. There is room for improving dietary intake. Future research aims to demonstrate the clinical importance and reveal the effect of nutritional interventions.

KEYWORDS
deficiencies, diet, nutrition, pulmonary hypertension

INTRODUCTION

Pulmonary Arterial Hypertension (PAH) is a lethal disease, caused by progressive remodeling of the pulmonary arterioles and subsequent development of right heart failure (RHF).1 End-stage disease is characterized by weight loss and cardiac cachexia. Several factors may contribute to malnutrition in PAH, such as changes in food intake with progression of disease, intestinal edema and malabsorption due to venous congestion and a low

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.
In addition, diuretics and PAH-specific medications including prostacyclin may affect bowel function and renal clearance. Finally, anorexia is common in chronically ill patients. Although malnutrition is well recognized in end-stage disease, so far little is known of the nutritional status in PAH patients who are stable under treatment. While iron and vitamin D deficiencies have been described in PAH, until now a comprehensive description of the nutritional status in PAH patients with vitamin and mineral status and nutritional intake is lacking. As a consequence, no evidence based dietary recommendations are available.

For this article, we aimed to provide a comprehensive assessment of the nutritional status, including vitamins and mineral levels and nutritional intake, and quality of life in PAH patients.

METHODS

Population

The data used in this study was derived from a prospective study testing a nutrition and lifestyle intervention in patients with pulmonary arterial hypertension (UPHILL study).

In total, 37 patients were included with the following inclusion criteria: idiopathic, hereditary or drug-related PAH, age <80 and >18 years, NYHA II or III and stable for at least 3 months, determined by a stable 6-min walk test (6MWT) with a difference of <10%, an estimated glomerular filtration rate and willing and able to sign the informed consent form. All participants provided written informed consent before any study-related procedures.

The UPHILL study was approved by the medical ethics committee with approval number 2018.538 and complies with the Declaration of Helsinki.

Questionnaires

Nutrition

The Dutch version of the HELIUS (HEalthy LIfe in an Urban Setting) food frequency questionnaire (FFQ) was used to assess dietary intake of fluid, sodium, and sugar per day. This FFQ was developed at the Amsterdam UMC in collaboration with the National Institute for Public Health and the Environment (RIVM) and the Wageningen University. The patients were given an online version of the FFQ and reported eating frequency and portion size of 238 food items they could have consumed in the previous 4 weeks. Average daily nutrient intake was calculated by multiplying the frequency of consumption by the consumed amounts and nutrient content per item using the NEVOTabel (supplement).

Quality of life

The SF-36 questionnaire was used for assessing QoL. The SF-36 is a set of generic, coherent, and easily administered QoL measures. These measures rely upon patient self-reporting and are widely utilized by managed care organizations for routine monitoring and assessment of care outcomes in adult patients.

Blood analysis

All blood samples were drawn and pre-analytically processed according to the routine laboratory protocols. All analyses were performed by an ISO15189:2012 accredited medical laboratory. The hematological parameters were analyzed with a NX1000 analyzer (Sysmex), the routine blood chemistry parameters were analyzed with a Cobas8000 analyzer (Roche). The trace metals were determined with Atomic Absorption Spectroscopy (Shimadzu) and all vitamins were analyzed chromatographically with HPLC (Shimadzu). All reported results did comply with the criteria of the external quality surveys.

6MWT

The 6MWT was used to assess exercise capacity. This test is widely used for measuring response to therapeutic interventions in pulmonary and cardiac diseases. The 6MWT measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 min and is a useful measurement for functional capacity.

Statistical analyses

Data are presented as mean ± (standard deviation or SD) for normally distributed data or as median [interquartile range or IQR] for non-normally distributed data. For non-normally distributed data, logarithmic transformation was performed before the analysis. Relationships between two continuous variables were assessed with Pearson’s correlations. A p-value of <0.05 was considered statistically significant. Statistical analyses and graphical illustrations were generated in R studio (version 3.5.2).
RESULTS

Patient characteristics

In total, we included 37 patients with a mean age of 48 ± 16 years. 16% of the subjects were males, the mean BMI was 25.39 ± 4.34, the median NTproBNP was 32.50 (IQR [78.18–257.25]), 61% received double therapy and the mean 6MWD was 503 ± 123 meters. Detailed patient characteristics and results can be found in Tables 1 and 2.

Intake

As shown in Figure 1a, 78% of patients had a fluid intake above 1500 ml and 31% had an intake above 2000 ml. The intake of fluid mostly came from tea, coffee, and water. As can be seen in Figure 1b, 87% of the females and all males in this population exceeded their advised daily sugar intake. Commonly chosen sugar-enriched products were: beverages, bakery, and candy. In this population, 25% had an intake of sodium above 2300 mg and 56% had an intake below 1800 mg (Figure 1c). Intake of sodium mainly came from grain products, chips, salted nuts, and processed meat and fish. The reference values were derived from nutritional guidelines for patients with

---

**TABLE 1** Patient characteristics

| Overall |  |
|---------|---|
| n       | 37 |
| Age - mean (SD) | 47.92 (16.25) |
| Gender - N_male(%) | 6 (16.2) |
| 6MWT - mean (SD) | 503.15 (122.66) |
| NTproBNP - median [IQR] | 132.50 [78.18–257.25] |
| NYHA | II |
| BMI - mean (SD) | 25.39 (4.34) |
| Therapy (%) |  |
| Mono | 6 (16.7) |
| Double | 22 (61.1) |
| Triple | 9 (22.2) |
| Endothelin antagonists - N (%) | 27 (75.0) |
| Phosphodiesterase inhibitors - N (%) | 33 (91.7) |
| Postacyclin p.o. - N (%) | 7 (19.4) |
| Postacyclin i.v. - N (%) | 5 (13.9) |
| Calcium antagonists - N (%) | 3 (8.3) |
| Diuretics - N (%) | 19 (52.8) |
| Vitamin K antagonists - N (%) | 19 (52.8) |

Abbreviations: 6MWT, 6-min walk test; BMI, body mass index; SD, standard deviation.

**TABLE 2** Dietary intake, QoL and 6MWT

| Females | Males |
|---------|-------|
| n       | 31    |
| n       | 6     |
| Dietary intake |  |
| Fluid in ml (median [IQR]) | 1839.25 [1528.19–2162.00] |
| Sodium in mg (median [IQR]) | 1569.72 [1101.05–2281.25] |
| Sugar in grams (median [IQR]) | 40.20 [29.38–77.68] |
| SF-36 |  |
| Physical functioning (median [IQR]) | 50.00 [35.00–65.00] |
| Social functioning (median [IQR]) | 50.00 [37.50–62.50] |
| Role physical limitations (median [IQR]) | 50.00 [0.00–100.00] |
| Role emotional limitations (median [IQR]) | 66.70 [33.33–66.70] |
| Mental health (median [IQR]) | 60.00 [56.00–64.00] |
| Vitality (median [IQR]) | 45.00 [40.00–50.00] |
| Bodily pain (median [IQR]) | 89.80 [67.30–100.00] |
| Average health (median [IQR]) | 40.00 [35.00–50.00] |
| Health change (median [IQR]) | 50.00 [25.00–50.00] |
| 6MWT |  |
| Distance in meters (median [IQR]) | 499.50 [399.50–546.25] |

Abbreviations: 6MWT, 6-min walk test; IQR, interquartile range; QoL, quality of life.
FIGURE 1  (See caption on next page)
cardiovascular disease from the American Heart Association. A significant correlation was found between the intake of sugar and fluid (Figure 2a); that is, the higher the consumption of sugar the more fluid was consumed. There was also a linear correlation between the intake of sugar and sodium (Figure 2b). There was no correlation found between fluid intake and use of diuretics.

Vitamin and mineral status

Serum vitamin analyses were performed in all patients and most outcomes were within normal range (Table 3). As illustrated in Figure 3a, only a minority of patients showed a low vitamin A level. Low vitamin K1 status was more prevalent, and was observed in 18 patients (60%) (Figure 3b) and there was no relation with the use of vitamin K antagonists. Vitamin K2 status was low in all patients. As expected, vitamin D deficiency was observed in 43% (Figure 3c), based on low 25-OH vitamin D values. Vitamin B12 values were within reference interval (130–700 pmol/L) in the majority of patients (Figure 3d). However, to assess vitamin B12 deficiency, values should be interpreted in relation to methylmalonic acid (MMA) levels. This is because the circulating vitamin B12 species do not reflect the intracellular activity of vitamin B12-dependent enzyme systems.11,12 It is therefore generally accepted that the functional vitamin B12 status is better reflected by the serum concentration of MMA and to a somewhat lesser extend homocysteine. Although the serum MMA concentration is age dependent, in guidelines a value of >350 nmol/L is commonly used as a cut-off criterium for a functional vitamin B12 deficiency. Interestingly, as can be observed in Figure 3e,f, 29% of patients’ vitamin B12 values were >130 pmol/L in combination with MMA > 350 nmol/L. To correct for possible confounding by inflammation and reduced kidney function, relations are also shown for patients with an estimated glomerulus filtration rate <60 ml/min or CRP > 5 mg/L.

Serum mineral analyses were performed in all patients and most outcomes were within normal ranges, as can been seen in Table 3 and Figure 4a–c for selenium, Pretzels are salty snacks such as nuts, chips, and salty biscuits.
|                         | Females | Males | Reference values        |
|-------------------------|---------|-------|-------------------------|
| **n**                   | 31      | 6     |                         |
| **General blood markers** |         |       |                         |
| Erythrocytes (median [IQR]) | 4.70 [4.38–5.19] | 5.50 [4.90–5.52] | Females 3.8–5.3 × 10^{12}/L | males 4.4–5.9 × 10^{12}/L |
| Hematocrit (median [IQR]) | 0.44 [0.41–0.47] | 0.47 [0.45–0.50] | 0.36–0.48 L/L | 0.42–0.51 L/L |
| Hemoglobin (median [IQR]) | 8.60 [8.30–9.55] | 9.70 [9.30–9.80] | 7.3–9.8 mmol/L | 8.4–10.9 mmol/L |
| Leukocytes (median [IQR]) | 7.92 [7.19–8.94] | 5.12 [4.85–5.25] | 3.5–11.0 × 10^{9}/L | 3.5–11.0 × 10^{9}/L |
| Trombocytes (median [IQR]) | 254.00 [221.00–301.00] | 200.00 [195.00–260.00] | 150–400 ×10^{9}/L | 150–400 ×10^{9}/L |
| MCV (median [IQR]) | 92.50 [90.35–96.60] | 89.90 [89.80–92.40] | 83–98 fl | 83–98 fl |
| Methylmalonic acid (median [IQR]) | 222.00 [186.75–442.75] | 176.50 [136.00–288.25] | <350 nmol/L | <350 nmol/L |
| RDW (median [IQR]) | 46.00 [44.00–48.35] | 40.45 [39.92–41.57] | 37.0–48.0 fl | 37.0–48.0 fl |
| ALP (median [IQR]) | 74.00 [61.00–87.00] | 68.00 [60.75–79.00] | <120 U/L | <120 U/L |
| ALAT (median [IQR]) | 18.00 [13.75–24.00] | 19.00 [16.50–22.25] | <0–34 U/L | <0–45 U/L |
| ASAT (median [IQR]) | 23.50 [20.75–27.50] | 27.50 [24.75–32.50] | <0–31 U/L | <0–35 U/L |
| Bilirubine (median [IQR]) | 7.00 [5.33–10.18] | 5.70 [5.00–11.00] | <17 µmol/L | <17 µmol/L |
| Gamma GT (median [IQR]) | 20.00 [17.00–43.00] | 28.00 [21.00–37.25] | 0–38 U/L | 0–55 U/L |
| Creatinine (median [IQR]) | 71.00 [61.75–84.25] | 79.00 [77.50–97.75] | 45–84 µmol/L | 59–104 µmol/L |
| EGFR (median [IQR]) | 79.00 [74.35–90.00] | 90.00 [80.72–92.40] | >90 ml/min | >90 ml/min |
| Urea (median [IQR]) | 5.65 [4.50–6.53] | 4.75 [4.45–5.20] | 18–60 years: 2.1–7.1 mmol/L, >60 years: 2.9–8.2 mmol/L | 18–60 years: 2.1–7.1 mmol/L, >60 year: 2.9–8.2 mmol/L |
| Albumin (median [IQR]) | 41.30 [39.20–42.60] | 48.60 [48.60–48.60] | 35–50 g/L | 35–50 g/L |
| CRP (median [IQR]) | 2.00 [1.00–3.25] | 1.00 [1.00–1.00] | <10 mg/L | <10 mg/L |
| Ferritine (median [IQR]) | 66.80 [27.60–161.00] | 94.55 [65.18–112.75] | 13–150 µg/L | 30–400 µg/L |
| Ferritin saturation% (median [IQR]) | 20.50 [16.25–27.25] | 27.50 [26.00–35.00] | 20%–60% | 20%–60% |
| TIBC (median [IQR]) | 62.50 [59.25–73.75] | 63.50 [61.25–65.75] | 45–81 µmol/L | 45–81 µmol/L |
| Transferrin (median [IQR]) | 2.51 [2.36–2.95] | 2.54 [2.46–2.61] | 2.00–3.60 g/L | 2.00–3.60 g/L |
| Cholesterol (median [IQR]) | 4.70 [4.20–5.39] | 4.43 [4.14–4.73] | <6.0 mmol/L | <6.0 mmol/L |
| Chol_ratio (median [IQR]) | 3.60 [2.89–4.24] | 3.24 [3.01–3.58] | <5.00 | <5.00 |
| HDL (median [IQR]) | 1.35 [1.13–1.68] | 1.36 [1.22–1.48] | 0.90–3.00 mmol/L | 0.90–3.00 mmol/L |
| LDL (median [IQR]) | 2.80 [2.24–3.24] | 2.63 [2.32–2.99] | <2.50 mmol/L | <2.50 mmol/L |
**TABLE 3** (Continued)

|                        | Females  | Males   | Reference values   |
|------------------------|----------|---------|--------------------|
| **Triglycerides**      |          |         | <2.00 mmol/L       |
| (median [IQR])         | 1.30 [0.90–1.89] | 1.29 [1.15–1.44] | <2.00 mmol/L       |
| **T3 (median [IQR])**  | 4.66 [4.30–5.10] | 5.51 [5.43–5.51] | 3.1–6.8 pmol/L     |
| **T4 (median [IQR])**  | 16.85 [16.10–18.12] | 16.05 [15.65–16.45] | 12.0–22.0 pmol/L   |
| **TSH (median [IQR])** | 1.60 [1.28–2.25] | 1.40 [1.04–3.00] | 0.27–4.2 mU/L      |
| **IgA (median [IQR])** | 2.06 [1.84–2.63] | 1.72 [1.64–2.25] | 0.70–4.00 g/L      |

**Minerals**

|                        | Females  | Males   | Reference values   |
|------------------------|----------|---------|--------------------|
| Calcium (median [IQR]) | 2.38 [2.31–2.45] | 2.40 [2.37–2.43] | 2.20–2.65 mmol/L   |
| **Chloride (median [IQR])** | 102.10 [100.55–103.30] | 101.65 [101.23–102.68] | 97–107 mmol/L   |
| Chrome (median [IQR])  | 7.50 [7.50–7.50] | 7.50 [7.50–7.50] | <15.0 nmol/L      |
| Copper (median [IQR])  | 20.00 [18.00–22.00] | 14.00 [13.00–16.00] | 12–29 µmol/L     |
| Iron (median [IQR])    | 13.15 [8.70–16.10] | 17.55 [16.50–23.18] | 10–25 µmol/L    |
| Magnesium (median [IQR]) | 0.87 [0.84–0.91] | 0.93 [0.90–0.94] | 0.70–1.05 mmol/L |
| **Phosphate (median [IQR])** | 1.06 [0.98–1.20] | 1.05 [0.92–1.24] | 0.80–1.40 mmol/L |
| Potassium (median [IQR]) | 4.18 [3.85–4.52] | 4.38 [4.24–4.65] | 3.2–4.7 mmol/L   |
| **Selenium (median [IQR])** | 1.02 [0.92–1.20] | 1.04 [1.03–1.10] | 0.8–1.8 µmol/L  |
| Zinc (median [IQR])    | 14.00 [13.00–15.00] | 14.00 [14.00–15.00] | 10–20 µmol/L    |
| Sodium (median [IQR])  | 139.10 [138.45–140.25] | 138.60 [138.02–139.33] | 135–145 mmol/L  |

**Vitamins**

|                        | Females  | Males   | Reference values   |
|------------------------|----------|---------|--------------------|
| A (median [IQR])       | 2.10 [1.75–2.45] | 2.10 [1.57–2.40] | 1.2–2.7 µmol/L     |
| **B1 (median [IQR])**  | 148.00 [137.75–198.25] | 153.50 [145.75–168.00] | 85–175 nmol/L   |
| B2 (median [IQR])      | 257.50 [239.75–290.75] | 265.50 [230.50–291.50] | 200–375 nmol/L   |
| B6 (median [IQR])      | 91.00 [71.00–112.50] | 118.00 [79.00–142.00] | 59–179 nmol/L   |
| B3 (median [IQR])      | 28.00 [26.00–31.00] | 30.00 [29.00–36.00] | 20–50 µmol/L     |
| B12 (median [IQR])     | 380.00 [267.25–546.75] | 463.50 [331.50–502.50] | 130–700 pmol/L  |
| Beta carotene (median [IQR]) | 0.60 [0.50–0.85] | 0.60 [0.45–1.20] | 0.3–1.9 µmol/L   |
| D hydroxy (median [IQR]) | 58.60 [44.85–86.45] | 43.75 [38.65–66.03] | 43–168 pmol/L   |
| E (median [IQR])       | 34.00 [28.50–38.50] | 31.25 [30.12–32.75] | 15–50 µmol/L     |
| Folic acid (median [IQR]) | 17.80 [10.83–24.85] | 14.85 [10.68–16.48] | >8.83 nmol/L     |
| K1 (median [IQR])      | 0.60 [0.50–1.10] | 1.15 [0.60–1.88] | 0.8–5.3 nmol/L   |

Abbreviation: ALP, alkaline phosphatase; ALAT, alanine transaminase; ASAT, aspartate transaminase; Chol_ratio, cholesterol ratio; CRP, C-reactive protein; eGFR, estimated glomerulus filtration rate; gamma-GT, gamma-glutamyl transferase; HDL, high-density lipoprotein; IgA, immunoglobulin A; IQR, interquartile range; LDL, low-density lipoprotein; MCV, mean corpuscular volume; RDW, red cell distribution width; T3, triiodothyronine; T4, thyroxine; TIBC, total iron binding capacity; TSH, thyroid stimulating hormone.
FIGURE 3  (See caption on next page)
copper, and magnesium. Transferrin saturation (Figure 4d) was < 20% in 32% of patients indicating iron deficiency. Selenium values < 100 ug/l were present in 41% of patients and related to vitality, a marker for QoL (Figure 4e). There were no further correlations found between QoL vitamin status or mineral status.

**DISCUSSION**

To assess the nutritional status in PAH we determined serum levels of vitamins and minerals and dietary intake. Using a combination of questionnaires and extensive blood analyses, we provide for the first time an overview of nutritional status in PAH patients (Figure 5) which is highlighted by newly found deficiencies in vitamin B12, K1, and selenium. In addition, we show that many PAH patients have elevated sugar and fluid intakes and a reduced sodium intake.

**Intake**

As compliance of dietary guidelines is measured through dietary intake, we subsequently investigated the nutrient intake of the patients with the HELIUS questionnaire. The HELIUS questionnaire is a large questionnaire with over 238 products to assess nutritional intake over the last four weeks. The HELIUS questionnaire has been described as suited for diverse populations, including urban settings, the elderly and patients with cardiovascular disease.7,13,14

We found a high intake of sugar, correlated to a high intake of fluid, and a low intake of sodium. High-glucose and insulin levels have been shown to increase salt and water retention and are closely associated with kidney dysfunction and PAH.15-17 In addition, we observed a close correlation between fluid intake and sugar intake, confirming the notion of dietitians that sugar causes thirst. Fluid restriction is important in HF. We observed that 78% of patients exceeded fluid intake. The relation between sugar and fluid intake should be taken into account when designing novel dietary guidelines for PAH patients.

Interestingly, the sodium intake in this group can be considered low; 56% of the population had an intake below 1800 mg and even 5.6% had an intake below 500 mg sodium, which is the minimum reference value for vital functions. Nutritional advice in HF has always focused on lowering sodium intake and maybe this guideline has been taken too strictly in PAH. Recent studies question sodium guidelines.18 As O'Donnel et al. conclude19,20 a sodium intake below 3000 mg (100% in this population) is as worse as a sodium intake above 5000 mg when it comes to cardiovascular disease. To extend, patients with PAH often use diuretics which also deplete minerals. This raises the question of whether a low sodium intake is sensible.

The main intake of sugar and sodium came from ultra-processed foods (UPF), such as sugared beverages, snacks, and bakery.21 In patients with pre-existing cardiovascular disease, a diet rich in UPF is associated with increased hazard of all cause and increased mortality.22 As described, sugar and fluid intake were linearly related and sodium intake was too low in the majority of patients. We suspect that single dietary guidelines are followed too strictly and that patients will probably benefit more from general nutritional advice in relation to PAH. Further research is needed to investigate optimal communication of interventions.

**Vitamin and mineral status**

Although overall vitamin and mineral status was preserved in the majority of patients, in a subset of patients values below reference could be observed. As previously described by us and others, 32% of patients...
FIGURE 4  (See caption on next page)
had an iron deficiency and 43% a vitamin D deficiency.3–6 An iron deficiency is common in heart failure,23 and a vitamin D deficiency is described as a worldwide problem.24 In 60% of our patients vitamin K1 deficiency was observed. In our study group vitamin K2 levels were too low to be detected, which is also described in the overall Dutch population.25 A low vitamin K status is associated with increased cardiovascular risk.25–27 In our cohort, half of the patients with vitamin K1 deficiency use vitamin K antagonists. This is line with previous findings demonstrating that vitamin K antagonists may influence serum level of vitamin K1.28,29 However, we observed normal serum levels of vitamin K1 in patients with vitamin K antagonists as well (Table 1). Vitamin K1 is mainly provided by dietary intake of green leafy vegetables and is also produced by gut bacteria.26 An explanation might be limited intake, however, another explanation is the altered microbiome.30,31 For this, further studies to nutritional intake, the altered microbiome, and the clinical relevance of vitamin K1 are warranted.

In our study, we found a high MMA level in combination with normal vitamin B12 levels in 29% of the patients, which suggests deficiency of functional vitamin B12.11,12 Adenosyl cobalamin (vitamin B12) is a co-factor of L-methylmalonyl-CoA mutase, the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. When there is a deficiency of adenosyl-cobalamin, excessive D-methylmalonyl-CoA (the precursor of L-methylmalonyl-CoA) is converted into MMA.32,33 In the overall population, a vitamin B12 deficiency has an estimated prevalence of 5%–10% up to 20%–30% amongst elderly and even higher in vegetarians and pregnant.34,35 An international cohort concluded that a vitamin B12 deficiency was rare in heart failure, however, MMA levels were not analyzed.36 Another study, that determined MMA levels in patients with heart failure, found a functional vitamin B12 deficiency in 43.8% of the population.37 The increased MMA levels we observed, could indicate a problem in vitamin B12 absorption in PAH-patients, due to the frequent use of proton pump inhibitors in this population and an altered microbiome.30,31 A functional vitamin B12 deficiency is characterized by, for example, fatigue, light headedness, tachycardia and cold extremities, which are overlapping features in PAH.11,12 In addition, these overlapping features and normal serum levels of vitamin B12 results in a delayed recognition of a functional vitamin B12 deficiency. Further research is needed to understand the clinical relevance of a functional vitamin B12 deficiency in PAH.

Another observation of interest in our study was that 41% of the patients had selenium levels <100 μg/L. Although selenium values were within the limits of normal, a recent study38 has suggested that in HF patients’ selenium levels of 70 μg/L are already associated with worse survival and QoL. In our study, low selenium was also associated with reduced quality of life measured with the SF-36. We demonstrated an association with vitality, other components of the SF-36 had no correlation with selenium. Selenium is a strong antioxidant and an important regulator of mitochondrial function.39 In PAH patients, further research should be performed to unravel the role of reduced selenium in PAH, its therapeutic potential and should demonstrate the role of dietary and/or supplementary intervention on selenium status.

**Strengths and limitations**

There are some limitations within our study. This is a small study including only 37 patients from a Dutch PAH...
cohort. In addition, our patients had mild forms of PAH, evident from the low median NTproBNP values and high 6MWD. Nevertheless, we could observe mineral and vitamin deficiencies that deserve further investigation in larger multicentre cohorts of patients.

We could not include healthy subjects to compare blood levels and nutrient intake. Instead, we compared our findings to reference values from literature. Since there are different reference values for some vitamin- and mineral levels for males and females and for dietary sugar intake, we performed sex-stratified analyses to analyze this data. There were only 6 males included for this article and therefore this group was too small to compare with females for statistical analyses.

To determine nutritional intake, we used the HELIUS questionnaire which is a very large questionnaire with over more than 57 pages. Patients were asked to fill in their dietary habits over the previous 4 weeks. Patients may have been unaware of their actual nutritional intake or may have had problems with focussing on a load of questions. This may lead to under or overreporting, although former research has found the HELIUS questionnaire very suitable.13,14

To determine nutritional status, it is common to discuss BMI. Although in our group, the BMI was normal (mean 25.39 ± 4.34), we did not include it in our determination for nutritional status. BMI may not be the most reliable marker due to bias for fluid retention, which is common in PAH.

CONCLUSION

This is the first comprehensive study of nutritional status in PAH. Vitamin and mineral status were overall normal, besides common deficiencies of vitamin D and iron. However, evidence was found of previously unreported deficiencies in vitamin B12, vitamin K1 and selenium. Further research is needed to understand the clinical relevance. The intake of sugar and fluid was elevated and sodium intake was reduced. Sugar and fluid intake were linearly related. To lower fluid intake an effective reduction of refined sugar intake to a maximum of 37.5 g per day for males and a maximum of 25 g per day for females, as stated in AHA guidelines, is advised. There appears to be an unmet need for improvement in nutritional intake.

ETHICS STATEMENT

Documented informed consent for publication has been obtained from each patient.

ACKNOWLEDGMENT

We gratefully thank Mary Nicolau from the department of public health of the Amsterdam University Medical Centre for providing us information on interpreting data from the HELIUS food frequency questionnaire. This investigator-sponsored study was financially supported by Janssen-Cilag B.V.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

ORCID

Chermaine T. Kwant @ChermaineKwant

REFERENCES

1. Galíe N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf AV, Beghetti M, Ghofrani A, Sanchez MAG, Hansmann G, Klepetko W, Lancellotti P, Mattucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoepер M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Española de Cardiología (English Edition). 2016;69:177.
2. Saitoh M, Rodrigues dos Santos M, von Haelings L. Muscle wasting in heart failure: the role of nutrition. Wien Klin Wochenschr. 2016;128:455–65.
3. Callejo M, Blanco I, Barberá JA, Perez-Vizcaino F. Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension. Nutrients. 2015;69:579.
4. Mehta J, Benavides J, Memarpour R, et al. The prevalence of vitamin D deficiency in pulmonary hypertension patients and its correlation with parameters of pulmonary hypertension severity. Available from: www.atjournals.org
5. Ruitter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37:1386–91.
6. Vinke P, Koudstaal T, Muskens F, van den Bosch A, Balvers M, Poland M, Witkamp RF, van Norren K, Boomars KA. Prevalence of micronutrient deficiencies and relationship with clinical and patient-related outcomes in pulmonary hypertension types I and IV. Nutrients. 2021;13:3923. https://doi.org/10.3390/nu13113923
7. Beukers MH, Dekker LH, de Boer EI, Perenboom CWM, Meijboom S, Nicolau M, de Vries JHM, Brants HAM. Development of the HELIUS food frequency questionnaires: ethnic-specific questionnaires to assess the diet of a multi-ethnic population in the Netherlands. Eur J Clin Nutr. 2015;69:579–84.
8. Brazier JE, Harper R, B Jones NM, et al. General practice validating the SF-36 health survey questionnaire: new outcome measure for primary care. Available from: https://doi.org/10.1136/bmj.305.6846.160
9. American Thoracic Society ATS Statement: Guidelines for the Six-Minute Walk Test this official statement of the American Thoracic Society was approved by the ATS Board of Directors March 2002. Available from: https://doi.org/10.1164/rccm.166/1/111

10. van Horn L, Carson JAS, Appel LJ, Burke LE, Economos C, Karmally W, Lancaster C, Lichtenstein AH, Johnson RK, Thomas RJ, Vos M, Wylie-Rosett J, Kris-Etherton P. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation. 2016;134:e505–29.

11. Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Available from: www.aafp.org/afp (2017).

12. Wollenbuttel BHR, Wouters HJCM, de Jong WHA, et al. Association of vitamin B12, methylenalonic acid, and functional parameters.

13. Visser M, Elstgeest LEM, Winkens LHH, Brouwer IA, Nicolaou M. Relative validity of the helius food frequency questionnaire for measuring dietary intake in older adult participants of the longitudinal aging study Amsterdam. Nutrients. 2020;12:1998.

14. Yau A, Adams J, White M, Nicolaou M. Differences in diet quality and socioeconomic patterning of diet quality across ethnic groups: cross-sectional data from the HELIUS dietary patterns study. Eur J Clin Nutr. 2020;74:387–96.

15. Rippe JM, Angelopoulos TJ. Fructose-containing sugars and cardiovascular disease. Adv Nutr. 2015;6:430–439.

16. Dinicolantonio JJ, Lucan SC. The wrong white crystals: not salt but sugar as aetiological in hypertension and cardiometabolic disease. Open Heart. 2014;1:e000167.

17. Horita S, Nakamura M, Suzuki M, Satoh N, Suzuki A, Seki G. Selective insulin resistance in the kidney. BioMed Res Int. 2016;2016:1–8. https://doi.org/10.1155/2016/5825170

18. Patel Y, Joseph J. Sodium intake and heart failure. Int J Mol Sci. 2020;21:9474.

19. O’Donnell M, Mente A, Yusuf S. Sodium intake and cardiovascular health. Circ Res. 2015;116:1046–57.

20. O’Donnell M, Mente A, Alderman MH, Brady AJB, Diaz R, Gupta R, López-Jaramillo P, Luft FC, Lüscher TF, Mancia G, Mann JFE, McCarron D, McKee M, Messerli FH, Moore LL, Narula J, Oparil S, Packer M, Prabhakaran D, Schutte A, Sliwa K, Staessen JA, Yancy C, Yusuf S. Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. Eur Heart J. 2020;41:3363–73.

21. Srour B, Fezeu LK, Kesse-Guyot E, Allès B, Méjean C, Andriansolo RM, Chazelas E, Deschamps M, Hercherg S, Galan P, Monteiro CA, Julic C, Touvier M. Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Santé). BMJ. 2019;31451. https://doi.org/10.1136/bmj.l1451

22. Bonaccio M, Costanzo S, di Castelnuovo A, Persichillo M, Magnacca S, De Curtis A, Cerletti C, Donati MB, de Gaetano G, Iacoviello L. Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Molisani study. Eur Heart J. 2022;43:213–24.

23. von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC. Heart failure. 2019;7:36–46.

24. Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18:153–65.

25. Geleijnse JM, Vermeer C, Grobbee DE, et al. Nutritional Epidemiology Dietary Intake of Menaquinone Is Associated with a Reduced Risk of Coronary Heart Disease: The Rotterdam Study 1. Available from: https://academic.oup.com/ijn/article/134/11/3100/4688389/2004).

26. Palmer CR, Blekkenhorst LC, Lewis JR, Ward NC, Schultz CJ, Hodgson JM, Croft KD, Sim M. Quantifying dietary vitamin K and its link to cardiovascular health: a narrative review. Food Funct. 2020;11:2826–37.

27. van Balleghoijen AJ, Beulens JW. The role of vitamin K status in cardiovascular health: evidence from observational and clinical studies. Curr Nutr Rep. 2017;6:197–205.

28. Eichinger S. Reversing vitamin K antagonists: making the old new again. 2022. Available from: http://ashpublications.org/hematology/article-pdf/2016/1/605/1251082/hem088392.pdf

29. Holmes Mv, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev. 2012;26:1–14.

30. Kim S, Rigatto K, Gazzana MB, Knorst MM, Richards EM, Pepine CJ, Raizada MK. Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 2020;75:1063–71.

31. Sharma RK, Oliveira AC, Yang T, Kim S, Zubcevic J, Aquino V, Lobaton GO, Goel R, Richards EM, Raizada MK. Pulmonary arterial hypertension-associated changes in gut pathology and microbiota. ERJ Open Res. 2020;6:253–2019.

32. Andrès E, Serraj K, Zhu J, Vermorken AJM. The pathophysiology of elevated vitamin B12 in clinical practice. QJM. 2013;106:505–15.

33. Ermens AAM, Vlasveld LT, Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem. 2003;36:585–90.

34. Pawlak R, Lester SE, Babatunde T. The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: A review of literature. Eur J Clin Nutr. 2014;68:541–548.

35. Allen LH. How common is vitamin B-12 deficiency? 1-3. Am J Clin Nutr. 2009;89(2):693S–96S. https://doi.org/10.3945/ajcn.2008.26947A

36. van der Wal HH, Comin-Colet J, Klip IT, Enjuanes C, Beverborg NG, Voors AA, Banasiak W, van Veldhuisen DJ, Brugueria J, Ponikowski P, Jankowska EA, van der Meer P. Vitamin B12 and folate deficiency in chronic heart failure. Heart. 2015;101:302–10.

37. Polytarchou K, Dimitroglou Y, Varvarousis D, Christodoulis N, Psachoulia C, Panteziou C, Mourouzis I, Pantos C, Manolis AS. Methylenalonic acid and vitamin B12 in patients with heart failure. Hellenic J Cardiol. 2020;61:330–37.

38. Bommer N, Grote Beverborg N, Hoes MF, Streng KW, Vermeer M, Dokter MM, IJMker J, Anker SD, Clanden JGF, Hillege HL, Lang CC, Ng LL, Samani NJ, Tromp J, van Veldhuisen DJ, Touw DJ, Voors AA, van der Meer P. Selenium and outcome in heart failure. Eur J Heart Fail. 2020;22:1415–23.

39. Wesselink E, Koekkoek WAC, Grefte S, Witkamp RF, van Zanten ARH. Feeding mitochondria: potential role of...
nutritional components to improve critical illness convalescence. Clin Nutr. 2019;38:982–95.

**SUPPORTING INFORMATION**
Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Kwant CT, van der Horst FAL, Bogaard HJ, de Man FS, Vonk Noordegraaf A. Nutritional status in pulmonary arterial hypertension. Pulm Circ. 2022:e12173. https://doi.org/10.1002/pul2.12173